Observational Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jun 26, 2024; 12(18): 3461-3467
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3461
Table 1 Baseline characteristics of the 80 patients, n (%)
Variable
Total (n = 80)
CHD (n = 20)
HF (n = 20)
CHD + HF (n = 20)
Control (n = 20)
P value
Age (yr)63.2 ± 9.864.1 ± 10.462.3 ± 9.663.5 ± 9.262.9 ± 9.90.87
Male45 (56.3)12 (60.0)11 (55.0)13 (65.0)9 (45.0)0.54
Hypertension52 (65.0)14 (70.0)13 (65.0)15 (75.0)10 (50.0)0.23
Diabetes32 (40.0)9 (45.0)8 (40.0)10 (50.0)5 (25.0)0.28
Dyslipidemia30 (37.5)8 (40.0)7 (35.0)9 (45.0)6 (30.0)0.67
Smoking29 (36.3)8 (40.0)7 (35.0)9 (45.0)5 (25.0)0.48
Clinical presentation0.41
    Stable angina37 (46.3)10 (50.0)8 (40.0)11 (55.0)8 (40.0)
    Unstable angina27 (33.8)8 (40.0)7 (35.0)8 (40.0)4 (20.0)
    Acute myocardial infarction16 (20.0)2 (10.0)5 (25.0)1 (5.0)8 (40.0)
LVEF55.6 ± 9.257.2 ± 8.654.1 ± 9.853.8 ± 9.456.9 ± 8.90.59
Table 2 Serum levels of cystatin C, monocyte/high-density lipoprotein cholesterol ratio, and uric acid
Variable
Total (n = 80)
CHD (n = 20)
HF (n = 20)
CHD + HF (n = 20)
Control (n = 20)
P value
Cys-C (mg/L)1.3 ± 0.41.5 ± 0.31.4 ± 0.41.7 ± 0.41.0 ± 0.2< 0.001
MHR0.9 × 1091.0 × 1090.9 × 1091.1 × 1090.7 × 109< 0.001
UA (μmol/L)424.2 ± 125.7469.2 ± 119.4437.1 ± 130.6508.5 ± 124.7347.4 ± 89.7 < 0.001
Table 3 Diagnostic value of serum cystatin C, monocyte/high-density lipoprotein cholesterol ratio, and uric acid for coronary heart disease and heart failure
Biomarkers
Cut-off value
Sensitivity
Specificity
PPV
NPV
Accuracy
AUC (95%CI)
Cys-C for CHD1.2 mg/L8085808582.50.86 (0.77–0.95)
MHR for CHD0.9 × 1098580778782.50.87 (0.78–0.96)
UA for CHD389 μmol/L7590868182.50.86 (0.77–0.95)
Cys-C for HF1.4 mg/L8580778782.50.88 (0.79–0.97)
MHR for HF1.0 × 1098085808582.50.87 (0.78–0.96)
UA for HF449 μmol/L8085808582.50.88 (0.79–0.97)
Cys-C for CHD + HF1.6 mg/L9085829287.50.93 (0.86–1.00)
MHR for CHD + HF1.1 × 1098590859087.50.91 (0.83–0.99)
UA for CHD + HF508 μmol/L8590859087.50.92 (0.84–1.00)